Revumenib in Combination With Azacitidine + Venetoclax in Patients NPM1-mutated or KMT2A-rearranged AML

Clinical trial NCT06652438 · RECRUITING

Trial details

NCT number: NCT06652438
Sponsor: Stichting Hemato-Oncologie voor Volwassenen Nederland
Status: RECRUITING
Phase: Phase 3
Study type: INTERVENTIONAL

Acute Myeloid Leukemia, Adult

Start date: 2025-05-05
Primary completion: 2029-12-13
Enrollment: 448

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.